Skip to Content Facebook Feature Image

KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation

News

KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation
News

News

KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation

2024-12-11 09:41 Last Updated At:09:50

TOKYO--(BUSINESS WIRE)--Dec 10, 2024--

Kioxia Corporation, a world leader in memory solutions, today announced that the cryptographic module used in KIOXIA CM7 Series PCIe ® 5.0 NVMe™ Enterprise SSDs has been validated to meet Federal Information Processing Standard (FIPS) 140-3, Level 2 for cryptographic modules.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209242540/en/

The FIPS 140-3 standard specifies a set of security requirements of the Cryptographic Module Validation Program administered by the National Institute of Standards and Technology (NIST), used as a security metric for federal agencies to procure validated IT equipment. Companies and federal agencies may prefer or may now be required to deploy newer, more stringent government standards – which SSDs validated to FIPS 140-3 requirements would meet. Compared to the previous FIPS 140-2 requirements, 140-3 provides higher standards for SSDs, including a stronger authentication method and updated implementation guidance.

Kioxia brought PCIe 5.0 technology to server and storage applications with the KIOXIA CM7 Series NVMe SSD. Targeted at enterprise applications and use cases – including artificial intelligence, high-performance computing, online transaction processing database, and data warehousing – KIOXIA CM7 Series drives bring enterprise performance, reliability and security to data center servers and storage.

KIOXIA CM7 Series SSD Key Features include:

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

*Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

KIOXIA CM7 Series PCIe 5.0 NVMe Enterprise SSD (Photo: Business Wire)

KIOXIA CM7 Series PCIe 5.0 NVMe Enterprise SSD (Photo: Business Wire)

LONDON (AP) — King Charles III has been “deeply touched” by the response to his update on his cancer treatment, Buckingham Palace said Saturday, adding that the monarch is pleased to have highlighted the value of screening programs for the disease.

Medics and health charities have praised the king for his openness, saying his statement on Friday had already prompted people to seek information about cancer.

In a strikingly personal video statement, the British monarch acknowledged that a cancer diagnosis can feel “overwhelming,” but said catching the disease early brings “the precious gift of hope.”

Here’s what to know about the king's condition and his message.

The 77-year-old king said in a statement broadcast Friday that his treatment schedule will be reduced in the new year, “thanks to early diagnosis, effective intervention and adherence to ‘doctors’ orders.’”

He encouraged others to take advantage of screening programs such as those for breast, bowel and cervical cancer offered by Britain’s public health service.

“Early diagnosis quite simply saves lives,” the king said in the statement aired during a “Stand Up to Cancer” telethon on TV station Channel 4. He said catching the disease early had allowed him “to continue leading a full and active life even while undergoing treatment.”

Charles has received outpatient treatment for almost two years. Buckingham Palace did not say the king is in remission, but that his treatment is moving to a “precautionary phase” and his condition will be monitored to ensure his continued recovery.

“I know from my own experience that a cancer diagnosis can feel overwhelming,” the king said in his video statement. “Yet I also know that early detection is the key that can transform treatment journeys, giving invaluable time to medical teams – and, to their patients, the precious gift of hope.”

Charles announced in February 2024 that he had been diagnosed with cancer, and, in a break from centuries of secrecy about royal health, he has since spoken about the illness, using his story to promote cancer awareness and treatment.

The openness has limits, though. The king has not disclosed what type of cancer he has or what kind of treatment he is receiving. The palace said it was an intentional decision designed to ensure his message reaches the widest possible audience.

The king’s cancer was discovered after treatment for an enlarged prostate. While doctors ruled out prostate cancer, tests revealed “a separate issue of concern,” palace officials said last year.

Charles suspended his public appearances for about two months after his diagnosis. Since returning to the public eye, he has visited cancer treatment centers across the country and shared stories with fellow patients.

Buckingham Palace said Charles “will be greatly encouraged and deeply touched by the very positive reaction" his message has generated. “He will be particularly pleased at the way it has helped to shine a light on the benefits of cancer screening programs,” it added.

British cancer charities said the number of people seeking information about cancer jumped after the king revealed he was undergoing treatment last year.

Cancer Research U.K. said about 100,000 people have visited its Screening Checker website since it was launched on Dec. 5, most of them since the king’s statement on Friday.

The charity's Chief Executive Michelle Mitchell said: “When public figures speak openly about their cancer diagnosis, it can prompt others to check in on their health.”

Broadcaster Jonathan Dimbleby, the king’s authorized biographer, said the statement was “a remarkable thing for a monarch to do.”

“It takes guts, and the fact that he came out and did that will save lives,’” Dimbleby said.

The Princess of Wales, who announced her own cancer diagnosis six weeks after her father-in-law, has also given updates on her treatment. Kate announced in January that her cancer is in remission.

Find more of AP’s coverage at https://apnews.com/hub/royalty

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Recommended Articles